Search Results - weizhao+chen

6 Results

Sort By:

Single domain CD4, HIV-1 Antibodies, and Fusion Proteins for treatment of HIV

Abstract: Soluble forms of human CD4 (sCD4) inhibit HIV-1 entry into immune cells. Different forms of sCD4 and their fusion proteins have been extensively studied in animal models and clinical trials as promising HIV-1 inhibitors. However, they have not been successful in clinical trials due to their transient efficacy. sCD4 is also known to interact...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Weizhao Chen

Keywords(s): CD4, Dimitrov, fusion protein, HIV-1, Single Domain Antibodies (sdAb)

Category(s): Application > Therapeutics, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing

HIV-1 Therapeutic Inhibits Viral Entry

Abstract: Soluble forms (sCD4) of human CD4, the HIV-1 primary receptor, are potent HIV-1 entry inhibitors. Both four-domain (D1-4) and two-domain (D1D2) sCD4 and their fusion proteins have been tested as candidate therapeutics in animal models and in human clinical trials and were well tolerated by patients with no significant clinical or immunologic...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Weizhao Chen, Prabakaran Ponraj

Keywords(s): CD4, entry inhibitor, HIV, MHCII, soluble expression

Category(s): Application > Therapeutics, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing, TherapeuticArea > Oncology

Antibodies and CARs Targeting FLT3 for the Treatment of Acute Myeloid Leukemia and Acute Lymphoid Leukemia

Abstract: Fms-like tyrosine kinase 3 (FLT3) is a cytokine receptor which belongs in the receptor tyrosine kinase class III. FLT3 is expressed on the surface of many hematopoietic progenitor cells and plays an important role in hematopoietic stem/progenitor cell survival and proliferation. It is often overexpressed in acute lymphoblastic leukemia (ALL)...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Weizhao Chen, Terry Fry, Christopher Chien, Haiying Qin

Keywords(s): acute lymphocytic leukemia, acute myeloid leukemia, ALL, AML, CANCER, cancer therapeutic, chimeric antigen receptor (CAR), Flt3, Monoclonal Antibody

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing

Fusion Proteins as HIV-1 Entry Inhibitors

Abstract: Soluble forms of human CD4 (sCD4) inhibit HIV-1 entry into immune cells. Different forms of sCD4 and their fusion proteins have been extensively studied as promising HIV-1 inhibitors – including in animal models and clinical trials. However, they have not been successful in human studies due to their transient efficacy. sCD4 is also known...

Published: 5/22/2024 | Inventor(s): Dimiter Dimitrov, Weizhao Chen, Tianlei Ying

Keywords(s): antibody dependent cellular cytotoxicity (ADCC), Class II major histocompatibility complex (MHCII), Dimitrov, fusion protein, HIV-1, sCD4

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease

Novel Fusion Proteins for HIV Vaccine

Abstract: Development of successful HIV vaccine immunogens continues to be a major challenge. Although gp120 was identified as having significant potential as a vaccine immunogen, attempts to elicit broadly neutralizing antibodies using recombinant gp120 failed. The highly flexible gp120 may present numerous conformations to the humoral immune system...

Published: 7/25/2024 | Inventor(s): Dimiter Dimitrov, Weizhao Chen

Keywords(s): ANTIBODY, CD4, Dimitrov, fusion protein, gp120, HIV Vaccine

Category(s): TherapeuticArea > Immunology, Application > Research Materials, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing

Identification and Use of Heterocyclic Alcohol Compounds for the Treatment of SULT1A1-expressing Cancers

This technology includes the identification and use of heterocyclic alcohol compounds, including RITA and N-BIC, for the treatment of SULT1A1-expression cancers. A high-throughput screen (qHTS) was performed using >1,000 caner cell lines identified a compound called YC-1 (also called Lificiguat) that is effective across cancer cell types that express...

Published: 7/25/2024 | Inventor(s): Min Shen, Ke Kong, Toble Lee, Samarjit Patnaik, Olivia Lee, Jonathan Shrimp, Mindy Davis, Juan Marugan, Wei Zhao, Matthew Hall

Keywords(s): Agents, Alcohol, anti-cancer, Class, compounds, HETEROCYCLIC, SULT1A1-dependent, VCXXXX, WKXXXX, XCXXXX, XEXXXX

Category(s): Application > Research Materials, Application > Therapeutics, Application > Diagnostics, TherapeuticArea > Oncology